We're making progress towards initiation of a Phase 2 trial for the MagSense® HER2 imaging agent. Our plans to submit an IND to the FDA is on track for Q3, and we’re thrilled to have Dr. William Dooley as Principal Investigator. Read More: $IBX

🚨Exciting news! We received positive FDA feedback on our planned Phase 2 trial for the MagSense® HER2 imaging agent, which means we can continue to advance our first-of-its-kind non-radioactive molecular MRI technology. Read more: $IBX #MagSense #FDA.

We’re honored to be featured in Stockhead’s latest article, highlighting Imagion Biosystems as one of the ASX-listed cancer-fighting stocks with strong investment potential. 🗞️ Read more: $IBX #CancerDiagnostics #ASXnews.

At our recent EGM, @imagionbio shareholders approved a $3M capital raise to support our IND filing — an essential step toward advancing our #MagSense imaging agent technology. We sincerely thank our shareholders for their trust and continued support! $IBX #CancerDetection #EGM

We’re in Chicago for #RSNA24 from Dec. 2-4! Join us and imaging professionals to discover innovations like #MagSense that are driving healthcare forward. Let us know if you’ll be there. 📍 Learn more about the meeting:  #Radiology #HealthcareInnovation

📢 Exciting corporate updates!.🔹 IND filing for HER2 Phase 2 Study set for mid-2025.🔹 $3M raise led by CPS Capital closes Dec .🔹 Welcoming Dr. Susan Harvey as Medical Affairs Advisor .🔹 Investor webinar on Nov 27, 9:00 am AEDT. Full update 👉 $IBX.

📢 Join our upcoming investor webinar on August 15 at 10am AEST! We'll outline the proposed EGM resolutions, share updates on our #MagSense technology, and discuss our strategic direction. Plus, participate in our live Q&A. Register now:.$IBX #IBX.

We're very pleased to welcome Brett Mitchell to Imagion Biosystems as a Non-Executive Director. With his wealth of experience in capital markets and the #ASX, we expect Brett will have a significantly positive impact. Welcome aboard, Brett > $IBX.

📰 We have released our Quarterly Activity Report and Appendix 4C for the period ending on 31 December 2023. Read the full announcement: $IBX.

[VIDEO] Following our announcement last week, CEO Dr. Isaac Bright shares Imagion's scientific presentation from SABCS, providing intricate insights into the Phase I Study conducted with #MagSense® HER2 Imaging Agent. Watch HERE ▶️ $IBX #CancerResearch.

🌟Latest study on MagSense HER2 Imaging Agent for breast cancer as an MRI adjunct shows it is safe and effective in distinguishing metastatic breast cancer. Blinded radiologists identified suspicious lymph nodes; no safety issues in 13 patients. More: $IBX

Exciting news! 🌟 Tomorrow at 7 am CST, Imagion presents groundbreaking data from our IBI10103 Phase I Study demonstrating the safety and clinical feasibility of Molecular MRI with #MagSense HER2 Imaging Agentat #SABCS23. Request the data: #Innovation $IBX

Note: Our ASX ticket will be IBXDA for a short period while the consolidation occurs.

⚠️ [IMPORTANT] Shareholders, our approved 40:1 share consolidation is now in effect starting today, 16 Nov 2023. Watch Dr. Bright discuss the consolidation in our EGM recording (at 19m:48s) here: $IBX

🎥 Learn about the latest developments at Imagion Biosystems' in this recording from our EGM on 13 November 2023. This event featured insights into our MagSense platform and addressed critical resolutions to be voted on by shareholders. Watch here: ▶️ $IBX

📰 We have released our Quarterly Activity Report and Appendix 4C for the period ending on 30 September 2023. Read the full announcement: $IBX #ASX #MolecularMRI.

🌸 We stand in the fight against breast cancer! Explore helpful early detection resources and read up on our team's inspiring stories 💕 💪 Together, we can make a difference. Learn more > 💻 #BreastCancerAwareness #PinkOctober #EarlyDetection $IBX

@Imagionbio CEO, Isaac Bright, presents our latest investor presentation at the @ShareCafe Hidden Gems webinar last week. Catch the webinar with Q&A session here 🎥: . $IBX #InvestorUpdate #innovation #molecularMRI

🎥 A video message from Imagion’s CEO, Isaac Bright - addressing the upcoming 2023 EGM Resolutions. Watch here: ▶️ $IBX #EGM #InvestorRelations

🎗️💓 Early detection saves lives! In honor of #BreastCancerAwarenessMonth this October, our team is sharing personal stories that drive us to make a difference in cancer detection. 🔬. Empower yourself with knowledge and read stories here: 💻 #PinkOctober